LB Pharmaceuticals Inc
corporate_fare Company Profile
LB Pharmaceuticals Inc (NASDAQ:LBRX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 24 items for LBRX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-06, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 11 rated 8 or above. Recent SEC coverage for LBRX spans 10-Q, 8-K, S-3ASR, 4.
Recent high-impact activity:
- Q3 Loss of $1.79 a Share Misses Consensus as R&D Spending Climbs
- LB Pharmaceuticals Q3 Loss Widens to $59.1M as Material Weaknesses Remain Unremediated
- LB Pharmaceuticals Posts $59.1M Q3 Loss; $403.8M Cash Funds Operations Past Q2 2029
- LB Pharma Files $200M ATM and Registers 8.5M PIPE Shares for Resale
- LB Pharma Q2 Loss Widens on Trial Costs; Material Weaknesses Persist; $150M Placement at Discount
Financial Snapshot
Short Interest & Short Volume
17.98 days to coverFINRA reported short interest of 6,199,068 shares in LBRX as of the October 30, 2026 settlement, a 11.4% increase from the prior period — about 18.0 days to cover at its recent average daily volume. On November 20, 2026, 56.1% of LBRX volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Moderate riskFiling-implied dilution signals for LBRX, detected from its recent SEC filings · based on capital-structure filings through 2026-10-01.
$200M ATM Program Launched · 8.49M PIPE Shares Registered for Resale
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →